(NASDAQ:LIEN) is a publicly traded Business Development Company that specializes in direct lending to middle-market private companies operating in sectors with regulatory or reputational challenges. Established in 2018, the company functions as an investment vehicle focused on private credit, originating loans through the platform of its parent entity, Chicago Atlantic.
As of early 2026, approximately 75% of its portfolio is concentrated in the medical cannabis production sector, with the remainder allocated to other regulated or high-risk industries. The firm has originated nearly 200 loans totaling over $3.3 billion since inception, and its current pipeline stands at $732 million, roughly double the size of the existing portfolio. This robust deal flow enables selective growth while maintaining credit discipline.
Portfolio Characteristics and Risk Management
Chicago Atlantic BDC maintains a conservative investment approach, with nearly 100% (99.5%) of its portfolio allocated to senior secured debt. The structure provides a high level of protection and recovery potential in the event of default. The company’s credit metrics compare favorably to the broader BDC universe: the weighted-average yield on debt investments reached 15.8% at the end of 2025, significantly above the sector average of 10.8%.
Interest coverage for borrowers stands at 2.5x, net debt-to-EBITDA is a modest 1.9x, and the share of non-accrual loans is zero – well below the peer average of 3.3%. The firm’s overall leverage remains extremely low at 0.08x debt-to-equity, compared with the BDC average of 1.2x.
At the end of 2025 the portfolio consisted of 39 borrowers with an average position size of approximately $8 million. The typical borrower generates annual revenue of approximately $83 million and EBITDA of $10 million, reflecting established businesses with positive cash flow rather than early-stage ventures.
Notably, the portfolio shows limited sensitivity to interest-rate declines, as 73% of loans feature either fixed rates or floating rates that have already reached their floor levels. 
Regulatory Tailwinds and Market Context
The U.S. medical cannabis market continues to expand rapidly. The number of states legalizing production and consumption grew from 35 in 2019 to 42 by the end of 2025, while industry revenue reached approximately $30-35 billion in 2025 and is projected to climb further in the coming years.
A significant catalyst occurred in December 2025 when President Trump issued an Executive Order directing the Attorney General to expedite the rescheduling of cannabis from Schedule I to Schedule III. This change, once fully implemented, would allow producers to deduct ordinary business expenses from their taxable income, potentially boosting after-tax cash flows by 20-40%.
In the broader private credit market, which is estimated at $1.3-2.1 trillion, current stress – driven by higher rates and elevated defaults in certain segments – has created attractive entry points. Chicago Atlantic BDC is well-positioned to capitalize on this environment, as its specialized focus on regulated niches offers higher yields while the parent platform provides a steady supply of high-quality opportunities.
Valuation and Investment Opportunity
Chicago Atlantic BDC currently trades at a discount of approximately 25% to its net asset value per share, which stood at around $13.30 at the end of 2025. This valuation gap appears excessive given the company’s stable fundamentals, zero non-accrual loans, and the positive regulatory developments in its core market. The shares offer a dividend yield of roughly 14%, supported by the high-yielding senior secured portfolio.
In a base-case scenario where the discount narrows meaningfully over the next two years – driven by continued portfolio growth, regulatory tailwinds, and a normalization in private credit sentiment – total annualized returns could exceed 25%, combining the dividend income with capital appreciation from NAV convergence.
Key Risks
The primary risks include potential changes in the regulatory environment for medical cannabis, which could lead to increased defaults within the concentrated portion of the portfolio. Sector concentration remains elevated at 75%, although management is gradually reducing this exposure through diversification. While the conservative underwriting and senior secured structure provide substantial downside protection, we should monitor both regulatory developments and the broader performance of the private credit market.
